# Natural killer cell as a potential predictive biomarker for early immune checkpoint inhibitor-associated cardiovascular adverse events: a retrospective cohort study

**Authors:** Yujuan Wu, Diansa Gao, Li Tan, Zhulu Chen, Chuan Zhang, Min Mao, Yuxi Zhu, Yue Liu, Zhong Zuo

PMC · DOI: 10.3389/fonc.2025.1556373 · Frontiers in Oncology · 2025-07-16

## TL;DR

This study found that higher baseline natural killer (NK) cell proportions may predict early cardiovascular side effects from immune checkpoint inhibitor therapy.

## Contribution

The study identifies baseline NK cell proportion as a novel predictive biomarker for early ICI-associated cardiovascular adverse events.

## Key findings

- Baseline NK cell proportion was an independent risk factor for CVAEs (p=0.009).
- ROC analysis showed baseline NK cell proportion had an AUC of 0.674 for predicting CVAEs.
- An optimal cutoff value of 16.4% for baseline NK cell proportion was confirmed via PSM.

## Abstract

Peripheral immune cells can predict responses to immune checkpoint inhibitor (ICI) therapy, but their relationship with early ICI-associated cardiovascular adverse events (CVAEs) is unclear. This study aimed to assess the predictive value of peripheral immune cells in early ICI-associated CVAEs.

Single-cell RNA sequencing (scRNA-seq) dataset from the Gene Expression Omnibus database was used to explore immune cell changes associated with ICI-associated CVAEs. Patients who had received ICI therapy for three cycles at the First Affiliated Hospital of Chongqing Medical University between November 2020 and November 2022 were then included. Patients were stratified into CVAEs and no CVAEs groups and compared peripheral immune cell subsets. Univariate and multivariate regression analyses were conducted to identify CVAEs risk factors. Receiver operating characteristic (ROC) curve analysis determined optimal cutoff values for potential biomarkers. Propensity score matching (PSM) was used to validate the predictive value of baseline NK cell proportion for CAVEs.

ScRNA-seq data revealed decreased CD8+ T and B cell proportions in the CVAEs group, while NK cell proportions increased. Among 203 patients, dynamic changes in the proportion of total T cell, CD8+ T cell, and NK cell differed significantly between groups. Baseline NK cell proportion was identified as an independent risk factor for CVAEs (p=0.009). ROC analysis identified baseline NK cell proportion as a potential predictor of CVAEs (AUC 0.674). The optimal cutoff value was determined to be 16.4%, and this finding was confirmed following PSM.

Baseline NK cell proportion was a potential predictor of early ICI-associated CVAEs.

## Full-text entities

- **Genes:** IGHD (immunoglobulin heavy constant delta) [NCBI Gene 3495], PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, CD8B (CD8 subunit beta) [NCBI Gene 926] {aka CD8B1, CD8beta, LEU2, LY3, LYT3, Ly-3}, KLRD1 (killer cell lectin like receptor D1) [NCBI Gene 3824] {aka CD94}, CDC14A (cell division cycle 14A) [NCBI Gene 8556] {aka DFNB105, DFNB32, DFNB35, cdc14, hCDC14}, IL32 (interleukin 32) [NCBI Gene 9235] {aka IL-32alpha, IL-32beta, IL-32delta, IL-32gamma, NK4, TAIF}, CX3CR1 (C-X3-C motif chemokine receptor 1) [NCBI Gene 1524] {aka CCRL1, CMKBRL1, CMKDR1, GPR13, GPRV28, V28}, BANK1 (B cell scaffold protein with ankyrin repeats 1) [NCBI Gene 55024] {aka BANK}, NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, GNLY (granulysin) [NCBI Gene 10578] {aka D2S69E, LAG-2, LAG2, NKG5, TLA519}, KLRF1 (killer cell lectin like receptor F1) [NCBI Gene 51348] {aka CLEC5C, NKp80}, BLK (BLK proto-oncogene, Src family tyrosine kinase) [NCBI Gene 640] {aka MODY11}, KLRB1 (killer cell lectin like receptor B1) [NCBI Gene 3820] {aka CD161, CLEC5B, NKR, NKR-P1, NKR-P1A, NKRP1A}, TNNT2 (troponin T2, cardiac type) [NCBI Gene 7139] {aka CMD1D, CMH2, CMPD2, LVNC6, RCM3, TnTC}, JCHAIN (joining chain of multimeric IgA and IgM) [NCBI Gene 3512] {aka IGCJ, IGJ, JCH}, CD247 (CD247 molecule) [NCBI Gene 919] {aka CD3-ZETA, CD3H, CD3Q, CD3Z, CD3ZETA, IMD25}, MS4A1 (membrane spanning 4-domains A1) [NCBI Gene 931] {aka B1, Bp35, CD20, CVID5, FMC7, LEU-16}, AQP3 (aquaporin 3 (Gill blood group)) [NCBI Gene 360] {aka AQP-3, GIL}, CD79B (CD79b molecule) [NCBI Gene 974] {aka AGM6, B29, IGB, Igbeta}, IGHG1 (immunoglobulin heavy constant gamma 1 (G1m marker)) [NCBI Gene 3500], CD79A (CD79a molecule) [NCBI Gene 973] {aka IGA, IGAlpha, MB-1, MB1}, MAL (mal, T cell differentiation protein (MAL blood group)) [NCBI Gene 4118] {aka HLD28, MVP17, VIP17}, IGLC3 (immunoglobulin lambda constant 3 (Kern-Oz+ marker)) [NCBI Gene 3539] {aka IGLC}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, IGHM (immunoglobulin heavy constant mu) [NCBI Gene 3507] {aka AGM1, MU, VH}, PRF1 (perforin 1) [NCBI Gene 5551] {aka HPLH2, P1, PFP}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, PCSK7 (proprotein convertase subtilisin/kexin type 7) [NCBI Gene 9159] {aka LPC, PC7, PC8, SPC7}, IGKC (immunoglobulin kappa constant) [NCBI Gene 3514] {aka HCAK1, IGKCD, Km}, IGHA1 (immunoglobulin heavy constant alpha 1) [NCBI Gene 3493] {aka IgA1}, CD7 (CD7 molecule) [NCBI Gene 924] {aka GP40, LEU-9, TP41, Tp40}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, FCGR3A (Fc gamma receptor IIIa) [NCBI Gene 2214] {aka CD16-II, CD16A, FCG3, FCGR3, FCRIIIA, FcGRIIIA}, IGHA2 (immunoglobulin heavy constant alpha 2 (A2m marker)) [NCBI Gene 3494], LTB (lymphotoxin beta) [NCBI Gene 4050] {aka TNFC, TNFSF3, TNLG1C, p33}, TNFAIP3 (TNF alpha induced protein 3) [NCBI Gene 7128] {aka A20, AIFBL1, AISBL, OTUD7C, TNFA1P2}, TCL1A (TCL1 family AKT coactivator A) [NCBI Gene 8115] {aka TCL1}
- **Diseases:** chest pain (MESH:D002637), thyroiditis (MESH:D013966), amaurosis (MESH:D001766), tachyarrhythmias (MESH:D013610), CVAEs (MESH:D002318), arrhythmia (MESH:D001145), sinus bradycardia (MESH:D012804), edema (MESH:D004487), myocardial tissue damage (MESH:D017695), cardiac biomarkers (MESH:D006331), inflammation (MESH:D007249), cancer (MESH:D009369), myocarditis (MESH:D009205), ECG abnormalities (MESH:D053840), COVID-19 (MESH:D000086382), CAD (MESH:D003324), ventricular tachycardia (MESH:D017180), syncope (MESH:D013575), hypertension (MESH:D006973), esophageal cancer (MESH:D004938), atrial fibrillation/flutter (MESH:D001282), atrioventricular block (MESH:D054537), lung cancer (MESH:D008175), heart failure (MESH:D006333), bradyarrhythmias (MESH:D001919)
- **Chemicals:** alcohol (MESH:D000438), pembrolizumab (MESH:C582435), Cy5.5 (MESH:C098793), ACEI (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12307152/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12307152/full.md

## References

35 references — full list in the complete paper: https://tomesphere.com/paper/PMC12307152/full.md

---
Source: https://tomesphere.com/paper/PMC12307152